CDK12 inactivation across solid tumors: an actionable genetic subtype

Inactivating CDK12 alterations have been reported in ovarian and prostate cancers and may have therapeutic implications; however, the prevalence of these mutations across other cancer types is unknown. We searched the cBioPortal and GENIE Project (public release v4.1) databases for cancer types with...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, Catherine H., Imada, Eddie L., Tang, Zhuojun, Marchionni, Luigi, Antonarakis, Emmanuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650168/
https://www.ncbi.nlm.nih.gov/pubmed/31360735
http://dx.doi.org/10.18632/oncoscience.481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650168/
https://www.ncbi.nlm.nih.gov/pubmed/31360735
http://dx.doi.org/10.18632/oncoscience.481

Ejemplares similares